The prevalence and significance of high-risk human papillomavirus DNA test in southern Malaysia and Singapore

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 49, Issue 3, 2009, Pages 323-327

  Tay, Sun Kuie ^a   Tay, Yeng Kwang ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; HPV vaccine; Hybrid Capture II; Liquid based cytology

Indexed keywords

VIRUS DNA;

ADULT; AGED; ARTICLE; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE; CANCER SCREENING; CONTROLLED STUDY; FEMALE; FOLLOW UP; GROUPS BY AGE; HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION; HUMAN; HUMAN CELL; HUMAN PAPILLOMA VIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; INFECTION RATE; MAJOR CLINICAL STUDY; MALAYSIA; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; SEROEPIDEMIOLOGY; SEROPREVALENCE; SINGAPORE; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS; AGE DISTRIBUTION; ALPHAPAPILLOMAVIRUS; GENETICS; INCIDENCE; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOLOGY; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; UTERINE CERVIX; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

ADULT; AGE DISTRIBUTION; AGED; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; DNA, VIRAL; FEMALE; HUMANS; INCIDENCE; MALAYSIA; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SINGAPORE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 70349770284     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2009.01000.x     Document Type: Article

References (26)

1. Bao YP, Li N, Smith JS et al. Human papillomavirus type distribution in women from Asia: A meta-analysis. Int J Gynecol Cancer 2008; 18: 71-79.
2. Waggoner SE. Cervical cancer. The Lancet 2003; 361: 2217-2225.
3. Schellekens MC, Dijkman A, Aziz MF et al. Prevalence of single and multiple HPV types in cervical carcinomas in Jakarta, Indonesia. Am J Pathol 2000; 157: 1055-1062.
4. Chicareon S, Herrero R, Munoz N et al. Risk factors for cervical cancer in Thailand: A case-control study. J Natl Cancer Inst 1998; 90: 50-57. (Pubitemid 28078081)
5. Bosch FX, Manos MM, Munoz N et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796-802.
6. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer 2003; 88: 63-73.
7. Seow A, Koh WP, Chia KS, Shi LM, Lee HP, Shanmugaratnam K. Incidence trends of cancer in Singapore 1968-2002. Singapore Cancer Registry Report No.6, 2004: 122-123.
8. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423-428.
9. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-265. (Pubitemid 34293391)
10. Brown DR, Shew ML, Qadadri B et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005; 191: 182-192.
11. Gravitt PE, Jamshidi R. Diagnosis and management of oncogenic cervical human papillomavirus infection. Infect Dis Clin North Am 2005; 19: 439-458.
12. Tay SK. Genital oncogenic human papillomavirus infection: A short review on the mode of transmission. Ann Acad Med Singapore 1995; 24: 598-601.
13. Tay SK, Ho TH, Lim-Tan SK. Is genital human papillomavirus infection always sexually transmitted? Aust N Z J Obstet Gynaecol 1990; 30: 240-242.
14. Moscicki AB, Shiboski S, Hills NK et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004; 364: 1678-1683.
15. Winer RL, Kiviat NB, Hughes JP et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005; 191: 731-738.
16. Rodriguez AC, Burk R, Herrero R et al. The natural history of human papillomavirus infection cervical intraepithelial neoplasia among young women guanacaste cohort shortly after initiation sexual life. Sex Transm Dis 2007; 34: 494-502.
17. Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24S3 2006: S3/ 26-S3/34.
18. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002r; 24;287: 2120-2129.
19. Saslow D, Runowicz CD, Solomon D et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002; 52: 342-362. (Pubitemid 35446606)
20. Woodman CB, Collins S, Winter H et al. Natural history of cervical human papillomavirus infection in young women: A longitudinal cohort study. Lancet 2001; 357: 1831-1836.
21. Khan MJ. Castle PE, Lorincz AT et al. The Elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-1079.
22. Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S. A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet 2005 May; 89: S4-S12.
23. Nanda K, Mccrory DC, Myers ER et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Int Med 2000; 132: 810-819.
24. Ferreccio C, Bratti MC, Sherman ME et al. A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. Cancer Epidemiol Biomarkers Prevention 2003; 12: 815-823.
25. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.
26. Paavonen J, Jenkins D, Boschfx Naud P et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-2170.